Ashvattha previews plans for long Covid trial in mid-2023
In an exclusive, Ashvattha Therapeutics CEO Jeff Cleland discusses a potential trial of OP-101 in long Covid patients experiencing chronic…
By
Drug Development
Latest in
Drug Development
Regenerative medicine deals dropped in the clinical trial operations in H1 2022
GlobalData's deals database looks at mergers, acquisitions and venture capital and private equity investments taking place worldwide.
By
Fauci: long Covid-19 trial endpoints ‘absolutely have to be standardised’
Clinical Trials Arena asks Dr Anthony Fauci about the biggest challenges to selecting long Covid-19 trial endpoints during a National…
By
Parkinson’s disease: major drug trial results to watch in 2022
Four clinical trials in Parkinson’s disease with readouts the second half of 2022 target motor symptom fluctuations and cognitive impairment.
By
‘How badly does it hurt?’ Challenges of measuring pain in clinical trials
Mapping Endpoints: Most clinical trials for pain still use a zero-to-ten scale as a primary endpoint. Experts are on the…
By
Beyond clinical trial design: factors that impact decentralisation
DCT Adoption Tracker: Clear regulatory guidance, existing healthcare infrastructure, and local culture are key influencers for swift decentralisation uptake.
By
Codagenix concludes subject dosing in Phase I influenza vaccine trial
CodaVax-H1N1 was developed using a codon-deoptimisation platform to exhibit all antigens of the naturally occurring virus.
HUYABIO commences dosing in Phase II atrial fibrillation drug trial
The trial will assess a single intravenous dose of HBI-3000 in AF patients between two and 72 hours.